Resembling a new era of innovative drug development, the interest of the biopharma industry in the oligonucleotide markets has grown significantly in the past five years.

In 2021, the US Food and Drug Administration (FDA) approved the first-in-class siRNA to lower cholesterol – a drug with a multi-ton potential to treat millions of patients per year. Moving forward, the demand for oligonucleotide batch size is likely to increase as well as the need for large-scale manufacturing capacity to support this growth.

Key Highlights:

• Sustainable Innovation: Discover how Bachem’s multi-column countercurrent solvent gradient purification (MCSGP) method significantly reduces solvent consumption and waste, making large-scale oligonucleotide API manufacturing more environmentally friendly.
• Enhanced Efficiency: Learn about the impressive improvements in throughput and productivity, with MCSGP reducing operation times and increasing yield compared to traditional batch chromatography.
• High Purity and Yield: Understand how Bachem achieves high purity and yield in oligonucleotide production while minimizing environmental impact, showcasing their expertise in large-scale manufacturing.

To download the entire resource, please complete the form.